HUS1600045I1 - Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával - Google Patents

Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Info

Publication number
HUS1600045I1
HUS1600045I1 HUS1600045C HUS1600045C HUS1600045I1 HU S1600045 I1 HUS1600045 I1 HU S1600045I1 HU S1600045 C HUS1600045 C HU S1600045C HU S1600045 C HUS1600045 C HU S1600045C HU S1600045 I1 HUS1600045 I1 HU S1600045I1
Authority
HU
Hungary
Prior art keywords
antibodies
methods
multiple myeloma
combination therapies
treating multiple
Prior art date
Application number
HUS1600045C
Other languages
English (en)
Original Assignee
Abbvie Biotherapeutics Inc
Dana-Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc, Dana-Farber Cancer Institute Inc filed Critical Abbvie Biotherapeutics Inc
Publication of HUS1600045I1 publication Critical patent/HUS1600045I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
HUS1600045C 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával HUS1600045I1 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
EP07840746.7A EP2068874B1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
HUS1600045I1 true HUS1600045I1 (hu) 2016-12-28

Family

ID=38831279

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE13168383A HUE029027T2 (hu) 2006-08-07 2007-08-07 Eljárások myeloma multiplex kezelésére HuLuc63 és bortezomib alapú kombinációs terápiák alkalmazásával
HUS1600045C HUS1600045I1 (hu) 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
HUS1600043C HUS1600043I1 (hu) 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
HUS1600044C HUS1600044I1 (hu) 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE13168383A HUE029027T2 (hu) 2006-08-07 2007-08-07 Eljárások myeloma multiplex kezelésére HuLuc63 és bortezomib alapú kombinációs terápiák alkalmazásával

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUS1600043C HUS1600043I1 (hu) 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
HUS1600044C HUS1600044I1 (hu) 2006-08-07 2016-10-20 Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával

Country Status (24)

Country Link
US (4) US8632772B2 (hu)
EP (5) EP2641601B8 (hu)
JP (1) JP5340935B2 (hu)
CN (1) CN101686971B (hu)
AU (1) AU2007281684C1 (hu)
BR (1) BRPI0716647A2 (hu)
CA (1) CA2660356C (hu)
CY (5) CY1116247T1 (hu)
DK (2) DK2641601T3 (hu)
ES (2) ES2535437T3 (hu)
HK (1) HK1129853A1 (hu)
HR (2) HRP20150449T1 (hu)
HU (4) HUE029027T2 (hu)
IL (2) IL196919A (hu)
LT (4) LT2641601T (hu)
LU (3) LU93275I2 (hu)
MX (1) MX2009001441A (hu)
NL (1) NL300840I2 (hu)
NO (1) NO346835B1 (hu)
NZ (1) NZ574978A (hu)
PL (2) PL2641601T3 (hu)
PT (2) PT2068874E (hu)
SI (2) SI2641601T1 (hu)
WO (1) WO2008019378A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660102C (en) * 2006-08-07 2017-02-21 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
CA2660356C (en) 2006-08-07 2016-04-05 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
CA2726804C (en) * 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
MX2010013833A (es) * 2008-06-16 2011-02-15 Immunogen Inc Nuevos efectos sinergisticos.
MX2011004225A (es) * 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
JP5709061B2 (ja) * 2009-09-10 2015-04-30 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
EP2504703B1 (en) * 2009-11-24 2016-11-16 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
CN105377288B (zh) 2012-11-05 2019-11-15 达纳-法伯癌症研究所股份有限公司 Xbp1、cd138和cs1肽的组合物制备药物的用途
US10494433B2 (en) 2013-11-06 2019-12-03 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
AU2014351996B2 (en) * 2013-11-21 2020-01-02 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
PL3182996T3 (pl) * 2014-08-22 2023-04-17 Celgene Corporation Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
CN107249632A (zh) * 2014-12-04 2017-10-13 百时美施贵宝公司 用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合
LT3294769T (lt) * 2015-05-13 2021-04-26 Morphosys Ag Daugybinei mielomai (dm) skirtas gydymas
EA035888B1 (ru) * 2015-06-29 2020-08-27 Бристол-Майерс Сквибб Компани Режимы дозирования иммунотерапевтических средств и их комбинаций
CN109498799A (zh) * 2016-03-13 2019-03-22 曹帅 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
SG11201907923VA (en) 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
CA3079751A1 (en) * 2017-11-22 2019-05-31 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP4055392A1 (en) 2019-11-05 2022-09-14 Bristol-Myers Squibb Company M-protein assays and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
CA2220971A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP2915533B1 (en) * 2002-05-17 2017-09-13 Celgene Corporation Pharmaceutical compositions for treating cancer
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
JP2008519028A (ja) * 2004-11-04 2008-06-05 フィブロン リミテッド Ｂ細胞悪性腫瘍の治療
CA2660102C (en) 2006-08-07 2017-02-21 Pdl Biopharma, Inc. Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
CA2660356C (en) 2006-08-07 2016-04-05 Pdl Biopharma, Inc. Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Also Published As

Publication number Publication date
DK2068874T3 (da) 2015-04-27
HRP20150449T1 (en) 2015-06-05
AU2007281684A1 (en) 2008-02-14
SI2641601T1 (sl) 2016-11-30
CA2660356C (en) 2016-04-05
US20140322201A1 (en) 2014-10-30
LU93276I2 (fr) 2016-12-27
HUS1600044I1 (hu) 2016-12-28
US20080152646A1 (en) 2008-06-26
LTPA2016029I1 (lt) 2016-11-10
SI2068874T1 (sl) 2015-06-30
HRP20161284T1 (hr) 2016-12-16
EP2641601B1 (en) 2016-07-06
NL300840I2 (hu) 2017-01-03
CY2016036I2 (el) 2017-07-12
CN101686971A (zh) 2010-03-31
HUS1600043I1 (hu) 2016-12-28
EP2068874B1 (en) 2015-01-28
IL196919A (en) 2016-03-31
US20160137735A1 (en) 2016-05-19
LU93277I2 (fr) 2016-12-27
EP2641600A1 (en) 2013-09-25
CY1117992T1 (el) 2017-05-17
PT2641601T (pt) 2016-10-14
ES2535437T3 (es) 2015-05-11
EP2641601A1 (en) 2013-09-25
PT2068874E (pt) 2015-05-21
CA2660356A1 (en) 2008-02-14
US8632772B2 (en) 2014-01-21
LU93275I2 (fr) 2016-12-27
BRPI0716647A2 (pt) 2017-05-16
LTPA2016030I1 (lt) 2016-11-10
ES2589302T3 (es) 2016-11-11
IL243933A0 (en) 2016-04-21
LTC2068874I2 (lt) 2018-11-12
CY2016036I1 (el) 2017-07-12
DK2641601T3 (en) 2016-08-22
EP2942057A1 (en) 2015-11-11
MX2009001441A (es) 2009-07-06
CY2016038I1 (el) 2017-07-12
EP2068874A1 (en) 2009-06-17
JP2010500371A (ja) 2010-01-07
EP2641601B8 (en) 2016-09-21
JP5340935B2 (ja) 2013-11-13
LT2641601T (lt) 2016-10-10
IL196919A0 (en) 2009-11-18
CY2016037I1 (el) 2017-07-12
HUE029027T2 (hu) 2017-01-30
CY1116247T1 (el) 2017-02-08
NZ574978A (en) 2012-08-31
CN101686971B (zh) 2013-09-11
PL2068874T3 (pl) 2015-06-30
NO346835B1 (no) 2023-01-23
AU2007281684B2 (en) 2013-05-16
NO20090968L (no) 2009-04-30
LTPA2016031I1 (lt) 2016-11-10
US20170342150A1 (en) 2017-11-30
AU2007281684C1 (en) 2013-12-19
WO2008019378A1 (en) 2008-02-14
HK1129853A1 (en) 2009-12-11
PL2641601T3 (pl) 2017-01-31
EP3115049A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
HUS1600043I1 (hu) Eljárások mielóma multiplex kezelésére, anti-CS1 ellenanyagokon alapuló terápiák kombinációjának alkalmazásával
IL304150A (en) Antibodies against 38cd for the treatment of multiple myeloma
HK1204994A1 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
IL193920A0 (en) Methods of treating lupus using cd4 antibodies
HK1129849A1 (en) Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
EP1998807A4 (en) METHODS OF HUMANIZING ANTIBODIES AND HUMANIZED ANTIBODIES THUS OBTAINED
IL243687A0 (en) For the treatment of multiple myeloma 1–cs antibodies against
ZA200807524B (en) Methods of treating lupus using CD4 antibodies
SI2068930T1 (sl) Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma
ZA200903242B (en) Treatment for multiple myeloma
HUS1700054I1 (hu) CD38-ellenes antitestek a mielóma multiplex kezelésére
LT1866338T (lt) Antikūnai prieš cd38, skirti daugybinės mielomos gydymui